J Clin Oncol. 2025 Sep 17:JCO2501148. doi: 10.1200/JCO-25-01148. Online ahead of print.
NO ABSTRACT
PMID:40961402 | DOI:10.1200/JCO-25-01148
Categories
Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence
